Literature DB >> 16831932

Bone destruction in multiple myeloma.

Toshio Matsumoto1, Masahiro Abe.   

Abstract

Multiple myeloma (MM) is characterized by accumulation of monoclonal plasma cells in the bone marrow and progression of lytic bone lesions. MM cells enhance bone resorption by triggering a coordinated increase in RANK ligand and decrease in osteoprotegerin in the bone marrow. Macrophage inflammatory protein (MIP)-1alpha and (MIP)-1beta are secreted by MM cells, and play a major role in the enhancement of bone resorption by MM cells. Furthermore, the growth and survival of MM cells are enhanced by contact with osteoclasts (OCs) suggesting the presence of a vicious cycle between OCs and MM cells. OCs also enhance angiogenesis in concert with MM cells largely through the cooperative actions of osteopontin from OCs and VEGF from MM cells. The angiogenic effect may further facilitate the vicious cycle between bone destruction and MM cell expansion. In addition, MM cells secrete soluble factor(s) to suppress bone formation. Secreted Frizzled-related protein (sFRP)-2, an inhibitor of Wingless type (Wnt) binding to Frizzled, is produced by most MM cells, and immunodepletion of sFRP-2 abrogates the inhibition of bone formation. Thus, MM cells enhance bone resorption and suppress bone formation to cause destructive bone lesions. Further elucidation of the mechanism of bone destruction by MM may lead to a novel therapeutic approach to prevent bone destruction and tumor growth.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16831932     DOI: 10.1196/annals.1346.035

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  13 in total

1.  Guest editorial: understanding the pathogenesis and the evolving treatment paradigm for multiple myeloma in the era of novel agents.

Authors:  Masahiro Abe
Journal:  Int J Hematol       Date:  2011-10-13       Impact factor: 2.490

2.  Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.

Authors:  Yu-Tzu Tai; Betty Y Chang; Sun-Young Kong; Mariateresa Fulciniti; Guang Yang; Yolanda Calle; Yiguo Hu; Jianhong Lin; Jian-Jun Zhao; Antonia Cagnetta; Michele Cea; Michael A Sellitto; Mike Y Zhong; Qiuju Wang; Chirag Acharya; Daniel R Carrasco; Joseph J Buggy; Laurence Elias; Steven P Treon; William Matsui; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2012-06-11       Impact factor: 22.113

Review 3.  Tissue engineered models of healthy and malignant human bone marrow.

Authors:  Alan Chramiec; Gordana Vunjak-Novakovic
Journal:  Adv Drug Deliv Rev       Date:  2019-04-17       Impact factor: 15.470

4.  Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth.

Authors:  Kyoko Takeuchi; Masahiro Abe; Masahiro Hiasa; Asuka Oda; Hiroe Amou; Shinsuke Kido; Takeshi Harada; Osamu Tanaka; Hirokazu Miki; Shingen Nakamura; Ayako Nakano; Kumiko Kagawa; Kenichiro Yata; Shuji Ozaki; Toshio Matsumoto
Journal:  PLoS One       Date:  2010-03-25       Impact factor: 3.240

5.  Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma.

Authors:  Ken-Ichi Kitazoe; Masahiro Abe; Masahiro Hiasa; Asuka Oda; Hiroe Amou; Takeshi Harada; Ayako Nakano; Kyoko Takeuchi; Toshihiro Hashimoto; Shuji Ozaki; Toshio Matsumoto
Journal:  Int J Hematol       Date:  2008-12-18       Impact factor: 2.490

6.  Targeting the Wnt signaling pathway to augment bone formation.

Authors:  Mohammad Shahnazari; Wei Yao; Maripat Corr; Nancy E Lane
Journal:  Curr Osteoporos Rep       Date:  2008-12       Impact factor: 5.096

7.  Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients.

Authors:  Anshu Marathe; Mark C Peterson; Donald E Mager
Journal:  J Pharmacol Exp Ther       Date:  2008-05-06       Impact factor: 4.030

8.  Differential expression of DKK-1 binding receptors on stromal cells and myeloma cells results in their distinct response to secreted DKK-1 in myeloma.

Authors:  Xiaoyi Dun; Hua Jiang; Jianfeng Zou; Jun Shi; Lili Zhou; Rong Zhu; Jian Hou
Journal:  Mol Cancer       Date:  2010-09-16       Impact factor: 27.401

Review 9.  Cytokine-mediated bone destruction in rheumatoid arthritis.

Authors:  Seung Min Jung; Kyoung Woon Kim; Chul-Woo Yang; Sung-Hwan Park; Ji Hyeon Ju
Journal:  J Immunol Res       Date:  2014-09-10       Impact factor: 4.818

10.  The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat.

Authors:  Mohannad Ashtar; Hirofumi Tenshin; Jumpei Teramachi; Ariunzaya Bat-Erdene; Masahiro Hiasa; Asuka Oda; Kotaro Tanimoto; So Shimizu; Yoshiki Higa; Takeshi Harada; Masahiro Oura; Kimiko Sogabe; Shingen Nakamura; Shiro Fujii; Ryohei Sumitani; Hirokazu Miki; Kengo Udaka; Mamiko Takahashi; Kumiko Kagawa; Itsuro Endo; Eiji Tanaka; Toshio Matsumoto; Masahiro Abe
Journal:  Cancers (Basel)       Date:  2020-04-09       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.